• LinkedIn
  • Twitter
Vesigen Therapeutics
  • About
    • Company Overview
    • Team
    • Investors
  • Our Science
  • Programs
  • News
  • Careers
  • Contact
  • Menu Menu
  • About
    • Company Overview
    • Team
    • Investors
  • Our Science
  • Programs
  • News
  • Careers
  • Contact

Our Science

Overcoming the challenges of drugging intracellular targets

Vesigen’s therapeutic programs employ engineered ARMMs to  deliver RNA, proteins, and gene-editing complexes to cells that are not  otherwise accessible. Unlike existing delivery systems, which are limited by toxicity, immunogenicity, poor cell/tissue specificity, and reduced cellular activity due to endosomal trapping or endolysosomal processing, ARMMs technology overcomes these limitation to achieve  safe and efficient functional delivery of therapeutic molecules.

Extracellular vesicles and ARMMs technology

Our technology is based on a distinct class of  extracellular vesicles that mediates  inter-cellular and inter-tissue signaling within the human body. ARMMs (ARRestin-domain 1 Mediated Microvesicles) technology derives its name from the protein ARRestin Domain Containing Protein 1 (ARRDC1), and utilizes the latter protein as a unique handle to actively recruit payloads into the intraluminal space.

ARMMs mediate intercellular receptor and cell-to-cell signaling and communication. This superior delivery mechanism supports a range of therapeutic applications.

Universal solution for drug development

Engineered ARMMs present a versatile platform for therapeutic delivery, with the potential to surpass the limitations of existing technologies such as toxicity, low specificity, instability, and high immunogenicity associated with lipid nanoparticles (LNPs), viral vectors, transducing peptides, and nano-carriers.

Vesigen’s ARMMs technology offers significant advantages over exosomes, LNPs, penetrating peptides, and viral delivery systems:

  • Broad tissue distribution observed in vivo
  • Streamlined payload production and formulation in a single process
  • Scalable production capabilities utilizing common upstream and downstream biologics process technologies
  • Superior engineerability with broad therapeutic applications

Engineered cells producing ARMMs loaded with green fluorescent protein (GFP)

Uptake of GFP-loaded ARMMs by recipient cells

Join our team

Explore current opportunities

  • About
  • Our Science
  • Programs
  • News
  • Careers
  • Contact

Vesigen Therapeutics
790 Memorial Drive
Suite 103
Cambridge, MA 02139

LinkeInTwitter

© 2020 Vesigen Therapeutics
All rights reserved.
Privacy Policy
Terms of Use

Design and development by RainCastle Communications
Scroll to top
  • About
    • Company Overview
    • Team
    • Investors
  • Our Science
  • Programs
  • News
  • Careers
  • Contact